Roupa Zoe, Noula Maria, Nikitara Monica, Ghobrial Savoula, Latzourakis Evangelos, Polychronis Giannis
Department of Life and Health Sciences, 121343University of Nicosia, Cyprus.
112431Cyprus Anti-cancer Society, Cyprus.
J Oncol Pharm Pract. 2022 Dec;28(8):1696-1703. doi: 10.1177/10781552211039489. Epub 2021 Sep 25.
The acceptance of an individual to be vaccinated following the introduction of a new vaccine is dependent on multiple factors. Governing factors directing one's decision to be vaccinated against severe acute respiratory syndrome coronavirus 2, however, are currently unknown and the present study aims at researching these factors within the population of cancer patients.
A cross-sectional self-administered survey was conducted anonymously between 22 January and 12 February 2021, during the second vaccination phase against severe acute respiratory syndrome coronavirus 2 in Cyprus. The data were collected via an online questionnaire which was formerly used by previously conducted studies. The Mann-Whitney test was applied for the comparison of means between bivariate variables, while the Kruskal-Wallis test was used for the comparison of means in variables with more than two groups. In addition, Spearman correlation coefficients were applied to explore the correlation of continuous variables.
The sample size consisted of a total of 211 cancer patients, 64.9% of which were women with a mean age of 52.6 ± 12.4 years. The findings of the current research indicate a moderate vaccination acceptance among cancer patients ( = 3.3 ± 0.7, = 1-5).
During the promotion of a vaccine against severe acute respiratory syndrome coronavirus 2 to cancer patients, particular emphasis on specific demographic characteristics, vaccination history and preferred sources of informing the individual are required. In addition, through reviewing the prospective effectiveness and possible outcomes of the specific vaccine according to cancer type and anti-cancer therapy, many of the existing concerns and reservations from cancer patients are expected to be diminished.
新疫苗推出后个体是否接受接种取决于多种因素。然而，指导人们决定接种严重急性呼吸综合征冠状病毒2疫苗的主导因素目前尚不清楚，本研究旨在研究癌症患者群体中的这些因素。
在2021年1月22日至2月12日期间，即塞浦路斯针对严重急性呼吸综合征冠状病毒2的第二阶段疫苗接种期间，进行了一项匿名的横断面自我管理调查。数据通过一份先前研究中使用过的在线问卷收集。采用曼-惠特尼检验比较双变量之间的均值，而克鲁斯卡尔-沃利斯检验用于比较两组以上变量的均值。此外，应用斯皮尔曼相关系数来探索连续变量之间的相关性。
样本量共计211名癌症患者，其中64.9%为女性，平均年龄为52.6±12.4岁。当前研究结果表明癌症患者的疫苗接种接受度中等（=3.3±0.7，=1-5）。
在向癌症患者推广严重急性呼吸综合征冠状病毒2疫苗时，需要特别强调特定的人口统计学特征、疫苗接种史以及个人偏好的信息来源。此外，通过根据癌症类型和抗癌治疗回顾特定疫苗的预期有效性和可能结果，有望减少癌症患者现有的许多担忧和疑虑。
